|
Post by saxcmann on Oct 26, 2016 19:48:23 GMT -5
I know right?! Hard to dilute more at these levels. Almost like they got cash coming?
|
|
|
Post by saxcmann on Oct 26, 2016 16:09:36 GMT -5
"From this perspective, a Dexcom/Afrezza co-promotion makes perfect sense. However, not sure if Matt and Mike (michaelcastagna ) can make this happen. One thing could be helpful is that Al Mann used to be mentor to Kevin Sayer (CEO of Dexcom)".
I also think dexcom/afrezza co-promotion makes perfect sense for both parties. This news could happen before end of year. Not sure what this does to pps or cash situation. Are we waiting for fda approval on dexcoms new device?
|
|
|
Post by saxcmann on Oct 25, 2016 13:52:02 GMT -5
Would be interesting to get a full count of the "validated referral on site" doctors as those are likely the ones that have at least one patient on Afrezza. My endo friend has over 20 pts on afrezza and not on "validated referral available" list. He also has a spirometry test and not on that list either...Hmm?
|
|
|
Post by saxcmann on Oct 25, 2016 11:20:45 GMT -5
That's what they have medical assistants for you know these days, the doctors, they only need money, only care about money , money first, patients second ... if they can have an easy solution or and they will not lose their license (because of warning labels, even is not true ) , they don't want to risk anything . Not true. They need scientific data and education so they understand the drug better. Still most docs don't understand how the dosing and titration works.
|
|
|
Post by saxcmann on Oct 25, 2016 11:18:09 GMT -5
also the doctor needs to fill the prior authorization form, everything is setting up to block afrezza to reach the market . usually the doctor doesn't want spend times too much on a new drug if he can use the old drug without going through the hassles .. their time is money so ... That's what they have medical assistants for Exactly! The Medical Assistant simply lets Mannkind cares handle insurance and titration issues once doc prescribes. It's really quite easy and simple for the endo. Yes, endos need to be educated so they understand the drug better. This is happening now. Drug dinners. Scripts will improve in my opinion, we just need cash to extend runway and dtc marketing...
|
|
|
Post by saxcmann on Oct 20, 2016 12:32:28 GMT -5
While the catalyst for today's move isn't known, it would be nice to find out it precedes a nice move up in tomorrow's scripts. There will always be those who know in advance. If one week delay you bet they'll know in advance. Maybe options in play?
|
|
|
Post by saxcmann on Oct 20, 2016 12:05:07 GMT -5
As always, more questions than answers and we can tell ourselves any narrative we would like. I still think the situation is precarious but on the positive side of the debate today, why would they be looking to fill 6 sales territories if it was over although I have seen companies hire and shortly thereafter terminate as the terminate order comes from a higher silo but for what its worth, see link below: touchpointsolutions.jobs/jobs/?q=mannkindAlso, Mike C does not seem to appear stressed out and the fact he is willing to share a photo / tweet of himself spending an afternoon at a football game could be construed as someone who is confident and will have runway to continue his commercialization strategy or if you want to take the opposing view, that he knows the end is near and he is simply enjoying life. I still believe he had to have some assurances about cash / runway before he left a stable job. If he were a neophyte in the industry, he would not know what questions to ask during his interview but he isn't and given he has reinvigorated ailing Rx products before, he knows many of the pitfalls and challenges. Of course, if I were 100% convinced of more cash and that the marketing plan simply needs time, I would pick up more shares - not there yet. They also hired my endo friend to speak a few weeks ago. I think others have been hired as well. Hmmm? Management doesn't seem concerned over cash currently do they? Almost feels like they are waiting for something before news can be released? Maybe just wishful thinking on my part? The current pps jump makes me think scripts could jump tomorrow? People in the know always know first....thoughts?
|
|
|
Cash
Oct 17, 2016 14:41:49 GMT -5
via mobile
Post by saxcmann on Oct 17, 2016 14:41:49 GMT -5
Matt, you and said that management, should they decide that ch 11 is the only option needs to file at a point in time where there is enough cash left to take the company through the process. In your opinion, how much cash would MNKD need to complete a ch 11? I cannot access Mannkinds website now but if they are still burning $10 mm / mo and they have enough cash to get the to Q1 '17 (per Matt P), my guess is that today, they have around $30 - $33 mm. Trying to get a handle on how much cash they have to run company and drop dead date they would need to file by. Per your earlier comments, you indicated that if the filing is inevitable, they would likely do so in conjunction with the next PR for the Q. Thanks, I have more than a bit of experience in bankruptcy cases, as a buyer of distressed assets for a former employer, as a consultant and expert witness for a distressed company that filed bankruptcy, and as a consultant and expert witness for a group of shareholders. Each case and the surrounding circumstances are unique but if I had to put a number to it I would guess that MNKD needs $50-60 million to make it through a reorganization. Let me break that down.
First, there is the expense of the attorneys. This will be a complicated case with lots of parties and there will be a lot of legal work. Bankruptcy attorneys are used to dealing with clients that are insolvent and will demand their estimated fees up front I the form of a retainer. While the fees are ultimately something that is approved on motion to the court, it gets paid out of that retainer. If assets are to be sold, there will be an asset liquidation firm appointed to write an offering memorandum for the saleable assets and that firm will be due a sale commission if successful. The company needs to file a detailed plan of reorganization with the court and there is typically a work-out firm that specializes in preparing those plan documents. If there is litigation between the bankruptcy estate and other parties, that creates another layer of legal fees. The Office of the US Trustee charges fees to administer the case. There are other costs of bankruptcy as well that I won't go into, but the debtor pays for most of it. The various retainers and expert fees will easily be in the ballpark of $10 million. Easily.
If the company is to reorganize life must go on during the pendency of the case. Afrezza has to be manufactured, salesmen have to call on physicians, financial reports have to be filed (although not with the SEC), and the office manager has to pay for lighting and air conditioning. We know the company is burning something like $8-10 million a month over and above what Afrezza sales bring in so over the course of a typical bankruptcy (120-180 days) the company will need to fund that operating burn. Additionally, all the accounts payable get frozen the instant the company files in court, which is good because creditors can't bring collection suits while the company is protected by the court, but at the same time a lot of vendors will put the company on cash terms. Prepaid deposits will have to be provided to all the utility companies to keep the lights, Internet, and telephones on. Any fudging that might have been possible by extended credit terms will be gone and MNKD will effectively turns into an all cash business. Quite literally you will have truck drivers demanding a check before they will unload supplies needed to continue operating.
So a monthly cash burn of $8-10 for 4-6 months plus the cost of the experts gets you to my estimated need for cash. On the supply side, the remaining Mann Group loan facility is $30.1 and the remaining ATM is restricted by the number of shares to a value of around $7 million at today's share price, so that is a total of $37 million of financing plus whatever is left on the balance sheet. As of June there was $63.7 million on the balance sheet and if we assume $8 monthly burn (it averaged $7 million in the first half of the year before the marketing effort) the balance sheet will be down to about $32 million by the end of October. If you use the $10 million monthly burn the cash remaining at the end of October is $24 million. For sake of argument lets use the midpoint of $28 million. Add the $28 million in cash remaining to the $37 in financing capacity and it comes to $66 million.
Without access to the books I can't be more precise that this, but it seems likely that at some point in November the cash required to operate the business as it goes through a bankruptcy reorganization will dip below the remaining cash assuming all the available sources of financing are tapped. There are potential surprises, both good and bad, that could change the math (like an RLS payment) but those are impossible to estimate.
Many companies can access debtor-in-possession (DIP) financing to access additional cash in bankruptcy, but DIP lines have to be secured by assets. Since Sanofi has a first priority security interest in the Valencia headquarters, and Deerfield Partners has a first priority security interest in Danbury, obtaining DIP finance is going to be extremely difficult. Getting around those security agreements will be almost impossible so I think the roughly $66 million MNKD can access is also close to 100% of what they can potentially access. More than anything else, I think that explains why the stock is trading where it is trading. Matt is running out of options and the market knows it. It's a plausible post for bankruptcy. But Mnkd knew it's cash would dwindle by 2017, 1st quarter, no? Mnkd has a contingency plan I bet, I hope.....right?!
|
|
|
Post by saxcmann on Oct 17, 2016 13:51:18 GMT -5
In the face of 95%, quickly approaching 100% losses, what's left other than hope and optimism? I believe in the product, but I consider myself a realist. I'm swayed neither by the bashers nor the pumpers, optimism has led me astray in this before so it's now been removed from my investing decisions. The situation is what it is. The company is in dire straights with new all time lows daily, Nasdaq de-listing, poor sales, and a quickly disappearing financial runway. But I'm not selling. My downside is limited to just a few more percentage points and I'm almost at a total loss already. What do I gain by selling now? My investment is sitting at a relative zero. I can either sell and hold absolute zero with no shares or hold for the possibility of recovery. I'll take door number #2. That being said, something needs to happen and quickly or my relative zero becomes absolute whether I like it or not. Can't agree more. I'm not selling now. We need good news soon or news will be bankruptcy or R/S in my opinion.
|
|
|
Post by saxcmann on Oct 14, 2016 13:13:53 GMT -5
I think the label has already been submitted for change. I think mnkd cares is handling all insurance issues now. I think mann foundation is another option to help financially. I think scripts need to continue to increase so we can get another partner. I think No to dilution. I think no to R/S. I think time is running out!! saxcmann about the label change, "I think the label has already been submitted for change". This is just your guess, correct? I want to see if you have any source of information on that. Not a guess. I have reasons to believe mnkd is in discussions with fda about label change. Can't say much more than that. We'll see if I'm right next time mnkd talks.
|
|
|
Post by saxcmann on Oct 14, 2016 11:08:25 GMT -5
I think the label has already been submitted for change. I think mnkd cares is handling all insurance issues now. I think mann foundation is another option to help financially. I think scripts need to continue to increase so we can get another partner. I think No to dilution. I think no to R/S. I think time is running out!!
|
|
|
Post by saxcmann on Oct 11, 2016 13:20:41 GMT -5
Nope, not me. They reached out to him. saxcmann that's great. I assume you are talking about the same "friend" you mentioned before. "To confirm what sports said mnkd is targeting currently prescribing endos first. Dr Combs will probably be hit soon. Mnkd has already met with my endo friend and it was very positive. They will meet again in late August. He is prescribing 2-4 afrezza PTs per week. mnkd has also reached out for him to speak. So things are moving well. Hope my feedback helps." Read more: mnkd.proboards.com/user/363/recent#ixzz4MnkazNtdYep, same friend.
|
|
|
Post by saxcmann on Oct 11, 2016 12:57:00 GMT -5
Great news Sports! Mnkd moving in the right direction. They even hired my endo friend to speak for them. Hopefully scripts jump in next few weeks. Maybe mnkd waiting for dexcom approval before dominos fall?? Anyone have any idea when fda might approve? Wow, saxcmann, I assume you facilitated that? Or was it mere coincidence? Nope, not me. They reached out to him.
|
|
|
Post by saxcmann on Oct 11, 2016 11:26:34 GMT -5
Great news Sports! Mnkd moving in the right direction. They even hired my endo friend to speak for them. Hopefully scripts jump in next few weeks. Maybe mnkd waiting for dexcom approval before dominos fall?? Anyone have any idea when fda might approve?
|
|
|
Post by saxcmann on Oct 10, 2016 9:58:12 GMT -5
My endo friend says Afrezza and Humalog are about the same after you figure in all the cost.
|
|